Abstract
Objective. To determine whether elevated soluble Fas/APO-1 (sFas/APO-1) levels are associated with either autoimmune disease or evidence of flares in auto-immune disease. Methods. Thirty-seven serum samples were retrospectively obtained from normal controls and patients with laboratory evidence of autoimmune disease activity. These samples were assayed for sFas/APO-1 levels by an enzyme-linked immunosorbent assay, and hospital medical records were retrospectively reviewed for clinical and laboratory characteristics of the patients. Results. Soluble Fas/APO-1 levels did not correlate with clinical diagnoses or laboratory abnormalities. The mean and range of sFas/APO-1 levels were similar in systemic lupus erythematosus patients (including those with active disease), patients with other autoimmune diseases, and normal controls. Conclusion. These data strongly suggest that measurement of sFas/APO-1 levels is unlikely to hold clinical value or play a role in the pathogenesis of autoimmune disease.
Original language | English (US) |
---|---|
Pages (from-to) | 1738-1743 |
Number of pages | 6 |
Journal | Arthritis and Rheumatism |
Volume | 38 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1995 |
Externally published | Yes |
ASJC Scopus subject areas
- Immunology
- Rheumatology